The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according ...

The money is not nearly enough to put two to four million people per year in South Africa on the lenacapavir jab, and even if it were, the country’s health system won’t be able to roll out the ...

A pharmacist holds a vial of lenacapavir, the injectable drug that prevents HIV infection. On June 18, the FDA approved the drug for use in the U.S. Nardus Engelbrecht/AP hide caption ...

Another study, the PURPOSE 1 trial, found that lenacapavir demonstrated 100% efficacy for HIV prevention in women. “Lenacapavir is a unique option for people for HIV prevention because it’s an ...